(Q38056540)

27 August 2017

title

Insulin detemir: a review of its use in the management of diabetes mellitus (English)

1 reference

27 August 2017

1 reference

1 reference

1

Gillian M Keating

1 reference

27 August 2017

publication date

1 December 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

72

1 reference

27 August 2017

issue

17

1 reference

27 August 2017

page(s)

2255-2287

1 reference

https://scigraph.springernature.com/pub.10.2165/11470200-000000000-00000

27 August 2017

exact match

0 references

cites work

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Pharmacology of insulin detemir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Crystal structure of a prolonged-acting insulin with albumin-binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Pharmacokinetics and pharmacodynamics of basal insulins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Does insulin detemir have a role in reducing risk of insulin-associated weight gain?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Cerebrocortical beta activity in overweight humans responds to insulin detemir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir is not transported across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferior

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Response to Comment on: Winkler et al. Histone Deacetylase 6 (HDAC6) Is an Essential Modifier of Glucocorticoid-Induced Hepatic Gluconeogenesis. Diabetes 2012;61:513–523.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Insulin detemir in routine clinical practice: a 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Standards of medical care in diabetes--2012

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Defining the role of insulin detemir in Basal insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

An analysis of dosing equivalence of insulin detemir and insulin glargine: more evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Patient perceptions of insulin detemir as reported through patient telephone surveys.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11470200-000000000-00000

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis

21 January 2018

1 reference

12 December 2020

Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries

1 reference

12 December 2020

Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans

1 reference

12 December 2020

Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue

1 reference

12 December 2020

Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States

1 reference

12 December 2020

Detemir as a once-daily basal insulin in type 2 diabetes

1 reference

12 December 2020

Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes

1 reference

12 December 2020

Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial

1 reference

12 December 2020

Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs

1 reference

12 December 2020

Insulin detemir for the treatment of obese patients with type 2 diabetes

1 reference

12 December 2020

The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries

1 reference

12 December 2020

Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus

1 reference

12 December 2020

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

1 reference

12 December 2020

Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data

1 reference

12 December 2020

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

1 reference

12 December 2020

Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas

1 reference

12 December 2020

Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study

1 reference

12 December 2020

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

12 December 2020

10.2165/11470200-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1009791830

0 references

1 reference